Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma

FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia

Suzanne Demko
Jeffrey Summers
Patricia Keegan
Richard Pazdur
Suzanne Demko
Jeffrey Summers
Patricia Keegan
Richard Pazdur

January 2015

located on the World Wide Web at: The online version of this article, along with updated information...

Sunitinib in the treatment of renal cell carcinoma: An update on recent evidence

Rizzo M.
Porta C.

January 2017

Sunitinib is a multitarget tyrosine kinase inhibitor endowed mainly by antiangiogenic effects, altho...

FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza™) for Injectable Suspension

Richard Pazdur
Edvardas Kaminskas
Ann T. Farrell
Yong-cheng Wang
Rajeshwari Sridhara
Edvardas Kaminskas
Ann T. Farrell
Yong-cheng Wang
Rajeshwari Sridhara
Richard Pazdur

January 2015

located on the World Wide Web at: The online version of this article, along with updated information...

Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma

David Morse
Ramzi Dagher
Robert Justice
Richard Pazdur
Edwin P. Rock
Vicki Goodman
Janet X. Jiang
Kooros Mahjoob
S. Leigh Verbois
Edwin P. Rock
A Vicki Goodman
A Janet X. Jiang
B Kooros Mahjoob
B S. Leigh Verbois
David Morse
A Ramzi Dagher
A Robert Justice
A Richard Pazdurc

January 2014

located on the World Wide Web at: The online version of this article, along with updated information...

Sunitinib (Sutent): A novel agent for the treatment of metastatic renal cell carcinoma

Jyoti D Chouhan
Daniel E Zamarripa
Phillip H Lai
Christine U Oramasionwu
Jodi L Grabinski

September 2016

In January 2006, sunitinib (Sutent) was approved by the Food and Drug Administration (FDA) for treat...

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That

Robert Justice
Richard Pazdur
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Overexpresses Her
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Rajeshwari Sridhara
Robert Justice
Richard Pazdur

January 1634

located on the World Wide Web at: The online version of this article, along with updated information...

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That

Robert Justice
Richard Pazdur
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Overexpresses Her
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Rajeshwari Sridhara
Robert Justice
Richard Pazdur

January 1634

located on the World Wide Web at: The online version of this article, along with updated information...

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That

Robert Justice
Richard Pazdur
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Overexpresses Her
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Rajeshwari Sridhara
Robert Justice
Richard Pazdur

February 2015

located on the World Wide Web at: The online version of this article, along with updated information...

journalsPermissions.nav Therapeutic Advances in Urology Review

Ther Adv Urol

September 2016

The advent of sunitinib malate (Sutent®, Pfizer Inc., NY, USA) for the first-line treatment of meta-...

Sunitinib treatment in a patient with metastatic renal cell carcinoma and bariatric surgery

Kinschot, C.M. van
Erp, N. van
Feberwee, T.
Dezentje, V.O.

January 2015

Contains fulltext : 154030.pdf (publisher's version ) (Closed access

journalsPermissions.nav Therapeutic Advances in Urology Review

Ther Adv Urol

September 2016

The advent of sunitinib malate (Sutent®, Pfizer Inc., NY, USA) for the first-line treatment of meta-...

journalsPermissions.nav Therapeutic Advances in Urology Review

Ther Adv Urol

September 2016

The advent of sunitinib malate (Sutent®, Pfizer Inc., NY, USA) for the first-line treatment of meta-...

FDA drug approval summary: erlotinib (Tarceva

Martin H. Cohen
John R. Johnson
Yeh-fong Chen
Rajeshwari Sridhara
Guest On M
Martin H. Cohen
John R. Johnson
Yeh-fong Chen
Rajeshwari Sridhara
Richard Pazdur

January 2005

The online version of this article, along with updated information and services, is located o

U.S. Food and Drug Administration Drug Approval

Nancy S. Scher
Gerald H. Sokol
Grant A. Williams
Richard Pazdur
Martin H. Cohen Ramzi Dagher
Summaries Imatinib Mesylate
Mesna Tablets
Martin H. Cohen
Ramzi Dagher
Donna J. Griebel
Amna Ibrahim
Alison Martin
Nancy S. Scher
Gerald H. Sokol
Grant A. Williams
Richard Pazdur

February 2015

located on the World Wide Web at: The online version of this article, along with updated information...

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence

Mimma Rizzo
Camillo Porta

August 2017

Sunitinib is a multitarget tyrosine kinase inhibitor endowed mainly by antiangiogenic effects, altho...

FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia

Suzanne Demko
Jeffrey Summers
Patricia Keegan
Richard Pazdur
Suzanne Demko
Jeffrey Summers
Patricia Keegan
Richard Pazdur

January 2015

located on the World Wide Web at: The online version of this article, along with updated information...

Sunitinib in the treatment of renal cell carcinoma: An update on recent evidence

Rizzo M.
Porta C.

January 2017

Sunitinib is a multitarget tyrosine kinase inhibitor endowed mainly by antiangiogenic effects, altho...

FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza™) for Injectable Suspension

Richard Pazdur
Edvardas Kaminskas
Ann T. Farrell
Yong-cheng Wang
Rajeshwari Sridhara
Edvardas Kaminskas
Ann T. Farrell
Yong-cheng Wang
Rajeshwari Sridhara
Richard Pazdur

January 2015

located on the World Wide Web at: The online version of this article, along with updated information...

Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma

David Morse
Ramzi Dagher
Robert Justice
Richard Pazdur
Edwin P. Rock
Vicki Goodman
Janet X. Jiang
Kooros Mahjoob
S. Leigh Verbois
Edwin P. Rock
A Vicki Goodman
A Janet X. Jiang
B Kooros Mahjoob
B S. Leigh Verbois
David Morse
A Ramzi Dagher
A Robert Justice
A Richard Pazdurc

January 2014

located on the World Wide Web at: The online version of this article, along with updated information...

Sunitinib (Sutent): A novel agent for the treatment of metastatic renal cell carcinoma

Jyoti D Chouhan
Daniel E Zamarripa
Phillip H Lai
Christine U Oramasionwu
Jodi L Grabinski

September 2016

In January 2006, sunitinib (Sutent) was approved by the Food and Drug Administration (FDA) for treat...

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That

Robert Justice
Richard Pazdur
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Overexpresses Her
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Rajeshwari Sridhara
Robert Justice
Richard Pazdur

January 1634

located on the World Wide Web at: The online version of this article, along with updated information...

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That

Robert Justice
Richard Pazdur
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Overexpresses Her
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Rajeshwari Sridhara
Robert Justice
Richard Pazdur

January 1634

located on the World Wide Web at: The online version of this article, along with updated information...

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That

Robert Justice
Richard Pazdur
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Overexpresses Her
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Rajeshwari Sridhara
Robert Justice
Richard Pazdur

February 2015

located on the World Wide Web at: The online version of this article, along with updated information...

journalsPermissions.nav Therapeutic Advances in Urology Review

Ther Adv Urol

September 2016

The advent of sunitinib malate (Sutent®, Pfizer Inc., NY, USA) for the first-line treatment of meta-...

Sunitinib treatment in a patient with metastatic renal cell carcinoma and bariatric surgery

Kinschot, C.M. van
Erp, N. van
Feberwee, T.
Dezentje, V.O.

January 2015

Contains fulltext : 154030.pdf (publisher's version ) (Closed access

journalsPermissions.nav Therapeutic Advances in Urology Review

Ther Adv Urol

September 2016

The advent of sunitinib malate (Sutent®, Pfizer Inc., NY, USA) for the first-line treatment of meta-...

journalsPermissions.nav Therapeutic Advances in Urology Review

Ther Adv Urol

September 2016

The advent of sunitinib malate (Sutent®, Pfizer Inc., NY, USA) for the first-line treatment of meta-...

FDA drug approval summary: erlotinib (Tarceva

Martin H. Cohen
John R. Johnson
Yeh-fong Chen
Rajeshwari Sridhara
Guest On M
Martin H. Cohen
John R. Johnson
Yeh-fong Chen
Rajeshwari Sridhara
Richard Pazdur

January 2005

The online version of this article, along with updated information and services, is located o

U.S. Food and Drug Administration Drug Approval

Nancy S. Scher
Gerald H. Sokol
Grant A. Williams
Richard Pazdur
Martin H. Cohen Ramzi Dagher
Summaries Imatinib Mesylate
Mesna Tablets
Martin H. Cohen
Ramzi Dagher
Donna J. Griebel
Amna Ibrahim
Alison Martin
Nancy S. Scher
Gerald H. Sokol
Grant A. Williams
Richard Pazdur

February 2015

located on the World Wide Web at: The online version of this article, along with updated information...

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence

Mimma Rizzo
Camillo Porta

August 2017

Sunitinib is a multitarget tyrosine kinase inhibitor endowed mainly by antiangiogenic effects, altho...

FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia

Suzanne Demko
Jeffrey Summers
Patricia Keegan
Richard Pazdur
Suzanne Demko
Jeffrey Summers
Patricia Keegan
Richard Pazdur

January 2015

located on the World Wide Web at: The online version of this article, along with updated information...

Sunitinib in the treatment of renal cell carcinoma: An update on recent evidence

Rizzo M.
Porta C.

January 2017

Sunitinib is a multitarget tyrosine kinase inhibitor endowed mainly by antiangiogenic effects, altho...

FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza™) for Injectable Suspension

Richard Pazdur
Edvardas Kaminskas
Ann T. Farrell
Yong-cheng Wang
Rajeshwari Sridhara
Edvardas Kaminskas
Ann T. Farrell
Yong-cheng Wang
Rajeshwari Sridhara
Richard Pazdur

January 2015

located on the World Wide Web at: The online version of this article, along with updated information...

Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma

Abstract

Extracted data

Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma

Abstract

Extracted data

Related items

Related items